Trial Profile
Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs CIGB 300 (Primary)
- Indications Cervical cancer; Condylomata acuminata; Genital warts
- Focus Adverse reactions; Therapeutic Use
- 30 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Jul 2012 New trial record